HOME > LATEST
LATEST
-
REGULATORY MHLW Panel Draws Up Plans for Generic Industry Shakeup in Final Report
May 23, 2024
-
REGULATORY Japan Govt to Launch Public-Private Forum to Attract Investments
May 23, 2024
-
REGULATORY No Inclusion of Males in National HPV Vaccinations for Now: MHLW Panel
May 23, 2024
-
BUSINESS AstraZeneca’s Beyfortus, Pfizer’s Elrexfio and More Now Available in Japan
May 23, 2024
-
BUSINESS Santen Recalls All Lots of Diquas LX, Halts Supply for Preservative Issue
May 23, 2024
-
REGULATORY Japan to Survey Uneven Distribution of Yakkasa, Look into Voluntary Chain Deals Too
May 23, 2024
-
BUSINESS Daiichi Sankyo Sets Up New Research Sites in US, Germany
May 23, 2024
-
BUSINESS Otsuka Axes Alzheimer’s Agitation Drug, Cuts Half-Year Profit Outlook
May 23, 2024
-
BUSINESS Bridion Generics Now Available; Maruishi to Launch on May 27
May 23, 2024
-
REGULATORY Fresh Panel Discussion for Avigan’s SFTS Use Set for May 24
May 23, 2024
-
BUSINESS Janssen Files Bispecific Teclistamab for MM in Japan
May 23, 2024
-
REGULATORY LDP Project Team Finalizes Proposal, Pushes Rethink of Off-Year Revisions
May 22, 2024
-
REGULATORY MOF Panel Urges Full-Scale Off-Year Revisions, Enhanced CEA: “Spring” Proposal
May 22, 2024
-
BUSINESS Japan Pharma Market Crosses 11 Trillion Yen in FY2023, Keytruda Triumphs: IQVIA
May 22, 2024
-
BUSINESS Biogen Files Tofersen as Japan’s 1st Genetic ALS Drug
May 22, 2024
-
BUSINESS Novo to Prioritize Markets for GLP-1 Supply, Touts Massive Lift in Capacity
May 22, 2024
-
BUSINESS Japan’s 1st Stelara Biosimilar to Hit Market on May 29
May 22, 2024
-
BUSINESS Servier Trains Sight on 50% Oncology Sales Ratio by 2030, Set to Upsize Japan Biz
May 22, 2024
-
REGULATORY Off-Year Price Revisions Should Either Be Abolished or Revisited: LDP Lawmakers
May 21, 2024
-
REGULATORY Bridion Sees Rare May Generic Entry for New Dosage Form in Japan
May 21, 2024
ページ
Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…